Literature DB >> 7797565

The SH2 domains of Src family kinases associate with Syk.

Y Aoki1, Y T Kim, R Stillwell, T J Kim, S Pillai.   

Abstract

Src family kinases (Lyn, Fyn, Lck, and Blk) and Syk, a tandem SH2 domain containing tyrosine kinase, have been demonstrated to be associated with the antigen receptor in B cells. Both of these categories of tyrosine kinases are presumed to be critical players in the process of antigen-mediated signal transduction. Cross-linking of membrane immunoglobulin on the surface of B cells leads to the activation of Lyn, Fyn, and Blk, which presumably associate with the cytoplasmic tails of the membrane immunoglobulin-associated Ig alpha/beta heterodimer. Receptor ligation also leads to the tyrosine phosphorylation and catalytic activation of Syk, but the mechanism of association of this kinase with the antigen receptor remains to be established. A number of phosphoproteins that can associate with the SH2 domains of Blk, Lyn, and Fyn have been described in activated B cells. We demonstrate here that Syk is one of the proteins in the lysates of activated B cells which bind to the SH2 domains of Src family kinases. Syk binds directly to the SH2 domain of Blk and complexes in vivo with Lyn and Blk in activated B cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797565     DOI: 10.1074/jbc.270.26.15658

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Sequential requirements of the N-terminal palmitoylation site and SH2 domain of Src family kinases in the initiation and progression of FcepsilonRI signaling.

Authors:  Z i Honda; T Suzuki; H Kono; M Okada; T Yamamoto; C Ra; Y Morita; K Yamamoto
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  The Activating C-type Lectin-like Receptor NKp65 Signals through a Hemi-immunoreceptor Tyrosine-based Activation Motif (hemITAM) and Spleen Tyrosine Kinase (Syk).

Authors:  Björn Bauer; Tanja Wotapek; Tobias Zöller; Emilia Rutkowski; Alexander Steinle
Journal:  J Biol Chem       Date:  2017-01-12       Impact factor: 5.157

3.  Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3.

Authors:  J Gao; K E Zoller; M H Ginsberg; J S Brugge; S J Shattil
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

4.  Concordance of increased B1 cell subset and lupus phenotypes in mice and humans is dependent on BLK expression levels.

Authors:  Ying-Yu Wu; Ina Georg; Alejandro Díaz-Barreiro; Nieves Varela; Bernard Lauwerys; Ramesh Kumar; Harini Bagavant; Mireia Castillo-Martín; Fadi El Salem; Concepción Marañón; Marta E Alarcón-Riquelme
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

5.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

6.  Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis.

Authors:  Ye Fan; Jin-Hui Tao; Li-Ping Zhang; Lian-Hong Li; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-12-09       Impact factor: 2.316

7.  The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.

Authors:  D H Chu; H Spits; J F Peyron; R B Rowley; J B Bolen; A Weiss
Journal:  EMBO J       Date:  1996-11-15       Impact factor: 11.598

8.  Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice.

Authors:  J Wang; T Koizumi; T Watanabe
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

9.  BLK polymorphisms and expression level in neuromyelitis optica spectrum disorder.

Authors:  Bo-Wen Yin; Bin Li; Arshad Mehmood; Congcong Yuan; Shuang Song; Ruo-Yi Guo; Lu Zhang; Tianzhao Ma; Li Guo
Journal:  CNS Neurosci Ther       Date:  2021-10-12       Impact factor: 5.243

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.